Brief: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
20/03/2025 20:52
March 20 (Reuters) - Vor Biopharma Inc VOR.O: VOR BIOPHARMA Q4 NET INCOME USD -30.7 MILLION VERSUS. IBES ESTIMATE USD -26.9 MILLION Source text: ID:nGNXXfCMn Further company coverage: VOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning